Skip to main content

Articles

Page 28 of 28

  1. Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate t...

    Authors: Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby and Wenyaw Chan
    Citation: Alzheimer's Research & Therapy 2010 2:2

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2010 2:14

  2. There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease...

    Authors: Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui and Rachelle S Doody
    Citation: Alzheimers Res Ther 2009 1:7
  3. Amyloid is deposited in the walls of arteries and capillaries as cerebral amyloid angiopathy (CAA) in the brains of older individuals and of those with Alzheimer disease (AD). CAA in AD reflects an age-related...

    Authors: Roy O Weller, Stephen D Preston, Malavika Subash and Roxana O Carare
    Citation: Alzheimer's Research & Therapy 2009 1:6
  4. Identifying the causes of dementia is important in the search for effective preventative and treatment strategies. The concept of mild cognitive impairment (MCI), as prodromal dementia, has been useful but rem...

    Authors: Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil and Carol Brayne
    Citation: Alzheimers Res Ther 2009 1:4